Kringle Pharma, Inc. (JP:4884) has released an update.
Kringle Pharma, Inc. reported an improved net sales figure of 61 million yen, a 19.3% increase, for the nine months ending June 30, 2024, compared to the previous year. Despite this, the company experienced significant operating losses, with basic earnings per share at a negative 82.76 yen. The company’s total assets rose to 2,941 million yen, with an equity ratio of 79.1%, and no changes to the dividend forecast were announced.
For further insights into JP:4884 stock, check out TipRanks’ Stock Analysis page.
